HLA-C and cancer: These MHC heavy chain polymorphisms are responsible for the generation of divergent peptide binding grooves and unique collections of MHC-presented peptides, which complicates the adoptive transfer of T-cells or specific TCR genes from individual-to-individual (as a universal cancer treatment, for instance) due to incomplete histocompatibility [14].